applications published 3 january 2007

Transdermal delivery of beneficial substances effected by a hostile biophysical environment
Strategic Science & Technologies 1737429*

Method of preparing low-crystallinity oltipraz or amorphous oltipraz
CJ Corp 1737430*

Method and device for releasing flavour and odour substances
Friedman, Tuvia; Chazot, Ahron 1737431*

Orally disintegrating tablets and methods of manufacture
Eurand Pharmaceuticals 1737432*

Taste-masked drugs in rupturing multiparticulates
Pfizer 1737433*

Apparatus and method for transdermal delivery of fentanyl-based agents
Alza Corp 1737434*

Fluid compsn used to simulate human synovial fluid
Ruch University Medical Center 1737435*

Prevention, treatment and amelioration of radiation induced enteritis
Salix Pharmaceuticals 1737436*

Novel use of peptide compounds for treating pain in painful diabetic neuropathy
Schwarz Pharma 1737437*

Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
Newron Pharmaceuticals 1737438*

Calcium salts for the treatment of psoriasis, dermatitis and dandruff
Bionest 1737439*

Use of PPAR delta agonists for treating demyelinating diseases
Aventis Pharmaceuticals 1737440*

Beneficial effects of increasing local blood flow
Strategic Science & Technologies 1737441*

Agonists of a bitter taste receptor and uses thereof
Deutsches Institut fuer Ernaehrungsforschung - Stiftung des oeffentlichen Rechts - Vertreten durch den Stiftungsvorstand 1737442*

Use of cis-epoxyeicosantrienoic acids and soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils
The Regents of the University of California 1737443*

C7 lactyloxy-substituted taxanes
Florida State University Research Foundation 1737444*

Method of treating Down syndrome
Axonyx 1737445*

Fused heterocyclic compounds
Bristol-Myers Squibb 1737446*

(R)-enoxamine sulphoxide and its use in the treatment of PDE-III mediated diseases
Myogen 1737447*

(S)-enoxamine sulphoxide and its use in the treatment of PDE-III mediated diseases
Myogen 1737448*

Pharmaceutical compsn
LEK Pharmaceuticals 1737449*

Aqueous compsn comprising thiazole derivative
R-Tech Ueno 1737450*

Monocyclic heterocycles as kinase inhibitors
Bristol-Myers Squibb 1737451*

Angiogenesis-affecting compounds and methods of use thereof
Angiogenetics Sweden 1737452*

Methods of using and compsns comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
Celgene Corp 1737453*

Method of food intake management
Mor Research Applications 1737454*

Controlled release pharmaceutical compsn of tolperisone for oral administration
Sanochemia Pharmazeuticka 1737455*

Medicament
Glaxo 1737456*

Use of a sphingoid base associated with nicotinic acid amide in the form of a depigmenting agent
Negma-Larads 1737457*

(R)-11-hydroxyaporphone derivatives and uses thereof
The McLean Hospital Corp 1737458*

Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents
Warner-Lambert 1737459*

Intermittent dosing regimen for the treatment of overweight with MTP-inhibitors
Janssen Pharmaceutica 1737460*

Carboline derivatives useful in the inhibition of angiogenesis
PTC Therapeutics 1737461*

Pyrimidines with TIE2 (TEK) activity
AstraZeneca 1737462*

Pyrimidines with TIE2 (TEK) activity
AstraZeneca 1737463*

Use of a trioxopyrimidine for the treatment and prevention of bronchial inflammatory diseases
F Hoffmann-La Roche; Universite de LiEge 1737464*

Compsn and method of decreasing renal ischaemic damage
Loma Linda University 1737465*

Combination of Y-aminobutyric acid modulators and 5-HT-1B receptor antagonists
Pfizer 1737466*

Method and compsn for treatment of skin conditions
Hutterer, Jeffrey 1737467*

Treatment of interstitial cystitis with vitamin D compounds
Bioxell 1737468*

Methods and compsns employing 4-aminophenylacetic acid compounds
Nobex 1737469*

Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compsns
Albion International 1737470*

Pharmaceutical compsns and methods of use of lipophilic, silicon-substituted, cyclooxygense-2 selective non-steroidal anti-inflammatory drugs and derivatives
RND Pharmaceuticals 1737471*

Effective treatment of tumours and cancer with triciribine and related compounds
University of South Florida 1737472*

Lithium combinations, and uses related thereto
Satow, Philip 1737473*

Non-GMO metal amino acid chelates and non-GMO metal amino acid chelate-containing compsns
Albion International 1737474*

Herbal therapy for the treatment of asthma
Li-Xiu-Min; Sampson, Hugh 1737475*

Materials and method for promotion of nerve regeneration
Emory University 1737476*

Therapeutic administration of the scrambled anti-angiogenic peptide C16Y
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services 1737479*

Pharmaceutical combined preparation containing a therapeutic protein
Hallstroem, Steh; Gasser, Harald 1737480*

Peptides of IL-1 beta and TNF alpha and method of treatment using the same
Vaxconsulting 1737481*

Compsns and methods for treating diseases
Lumen Therapeutics 1737482*

Cell death modulation via antagonists of FASL and FAS activation
University of Pittsburgh of the Commonwealth System of Higher Education 1737483*

Combination dosing regimen for erythropoietin
Janssen Pharmaceutica 1737484*

Mucinous glycoprotein (MUC-1) vaccine
Biomira 1737485*

Immunising against meningococcal serogroup Y using proteins
Chiron 1737486*

Method for treating autoimmune diseases with antibodies
Canadian Blood Services 1737487*

Treatment of fungal infections
Neutec Pharma 1737488*

ERBB antagonists for pain therapy
Agus, David 1737489*

Methods for treating autoimmune and inflammatory diseases
NovImmune 1737490*

Multiple-variable dose regimen for treating TNF alpha related disorders
Abbott Biotechnology 1737491*

Preparation for the photodynamic control of micro-organisms and use of said preparation
Helbo Photodynamic Systems 1737492*

Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumour cell growth
Dana-Farber Cancer Institute 1737493*

Freeze-dried, free-flowing, particulate compsn having improved palatability
Chiesi Farmaceutici 1737494*

Novel pharmaceutical or cosmetic carriers containing cyclic acetals
Gattefosse 1737495*

Novel G-CSF conjugates
Nektar Therapeutics 1737496*

Nucleic acid aptamers conjugated to high molecular weight steric groups
(OSI) Eyetech 1737497*

Zinc finger proteins for the treatment of neuropathic pain
Sangamo BioSciences 1737498*

Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
Arriva Pharmaceuticals 1737499*

Bioresponsive polymer system for delivery of microbicides
The University of Utah Research Foundation 1737500*

Fluid treatment system
Trojan Technologies 1737501*